Long-Term Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 244-Week Results From the KEEPsAKE 2 Trial. (2025). SKIN The Journal of Cutaneous Medicine, 9(6), s692. https://doi.org/10.25251/w6str133